Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

Prostate Cancer and Prostatic Diseases ◽

10.1038/sj.pcan.4500916 ◽

2006 ◽

Vol 10 (1) ◽

pp. 87-93 ◽

Author(s):

M Wirth ◽

◽

C Tyrrell ◽

K Delaere ◽

M Sánchez-Chapado ◽

...

Keyword(s):

Prostate Cancer ◽

Standard Care ◽

Metastatic Prostate Cancer ◽

Cancer Trial ◽

Early Prostate Cancer

Download Full-text

1181: Bicalutamide 150 MG in Addition to Standard Care in Patients With Early, Non-Metastatic Prostate Cancer: Results from the SPCG-6 Study at a Median Follow-up of 5.3 Years

The Journal of Urology ◽

10.1016/s0022-5347(18)38418-0 ◽

2004 ◽

Vol 171 (4S) ◽

pp. 311-312 ◽

Author(s):

Peter Iversen

Keyword(s):

Prostate Cancer ◽

Standard Care ◽

Metastatic Prostate Cancer

Download Full-text

1062: Bicalutamide 150 mg in Addition to Standard Care Significantly Improves Prostate Specific Antigen Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer: Median 5.4 Years' follow-up

The Journal of Urology ◽

10.1016/s0022-5347(18)38299-5 ◽

2004 ◽

Vol 171 (4S) ◽

pp. 280-281 ◽

Author(s):

William A. See ◽

Peter Iversen ◽

David G. McLeod ◽

Manfred P. Wirth ◽

Kevin Carroll ◽

...

Keyword(s):

Prostate Cancer ◽

Prostate Specific Antigen ◽

Standard Care ◽

Metastatic Prostate Cancer ◽

Specific Antigen ◽

Progression Free Survival ◽

Download Full-text

810: Bicalutamide 150 MG Alone or as Adjuvant to Standard Care Significantly Improves Progression-Free Survival in Patients with Early, Non-Metastatic Prostate Cancer (Median 5.4 Years' Follow-Up)

The Journal of Urology ◽

10.1016/s0022-5347(18)38059-5 ◽

2004 ◽

Vol 171 (4S) ◽

pp. 214-214 ◽

Author(s):

William A. See ◽

Peter Iversen ◽

David G. McLeod ◽

Manfred P. Wirth ◽

Thomas Morris ◽

...

Keyword(s):

Prostate Cancer ◽

Standard Care ◽

Metastatic Prostate Cancer ◽

Progression Free Survival ◽

Download Full-text

182 Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy significantly improves progression-free survival in early non-metastatic prostate cancer: Results from the bicalutamide early prostate cancer programme after a median 5.4 years' follow-up

European Urology Supplements ◽

10.1016/s1569-9056(04)90183-2 ◽

2004 ◽

Vol 3 (2) ◽

pp. 48 ◽

Author(s):

D. McLeod ◽

P. Iversen ◽

W. See ◽

M. Wirth ◽

K. Carroll ◽

...

Keyword(s):

Prostate Cancer ◽

Metastatic Prostate Cancer ◽

Progression Free Survival ◽

Free Survival ◽

Early Prostate Cancer

Download Full-text

Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer Updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

Scandinavian Journal of Urology and Nephrology ◽

10.1080/00365590601017329 ◽

2006 ◽

Vol 40 (6) ◽

pp. 441-452 ◽

Author(s):

Peter Iversen ◽

Jan-Erik Johansson ◽

Pär Lodding ◽

Timo Kylmälä ◽

Per Lundmo ◽

...

Keyword(s):

Prostate Cancer ◽

Standard Care ◽

Metastatic Prostate Cancer ◽

Download Full-text

Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme

Prostate Cancer and Prostatic Diseases ◽

10.1038/sj.pcan.4500799 ◽

2005 ◽

Vol 8 (2) ◽

pp. 194-200 ◽

Author(s):

M Wirth ◽

◽

C Tyrrell ◽

K Delaere ◽

M Sánchez-Chapado ◽

...

Keyword(s):

Prostate Cancer ◽

Standard Care ◽

Phase Iii ◽

Double Blind ◽

Early Prostate Cancer ◽

Phase Iii Study

Download Full-text

1013: Prostate-Specific Antigen Levels as a Predictor of Positive Bone Scans During Follow-Up After Standard Care for Prostate Cancer: Data from the Bicalutamide Early Prostate Cancer Program

The Journal of Urology ◽

10.1016/s0022-5347(18)35169-3 ◽

2005 ◽

Vol 173 (4S) ◽

pp. 275-275 ◽

Author(s):

Gerald W. Chodak ◽

Peter Iversen ◽

David G. McLeod ◽

William A. See ◽

Manfred P. Wirth ◽

...

Keyword(s):

Prostate Cancer ◽

Prostate Specific Antigen ◽

Standard Care ◽

Specific Antigen ◽

Cancer Data ◽

Early Prostate Cancer ◽

Cancer Program ◽

Download Full-text

1588: The Bicalutamide Early Prostate Cancer Program: Findings of the North American Trial at 7.7 Years' Median Follow-Up

The Journal of Urology ◽

10.1016/s0022-5347(18)33780-7 ◽

2006 ◽

Vol 175 (4S) ◽

pp. 511-512

Author(s):

David G. McLeod ◽

Ira Klimberg ◽

Donald Gleason ◽

Gerald Chodak ◽

Thomas Morris ◽

...

Keyword(s):

Prostate Cancer ◽

North American ◽

Early Prostate Cancer ◽

The North ◽

Download Full-text

[68Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?

EJNMMI Research ◽

10.1186/s13550-019-0554-1 ◽

2019 ◽

Vol 9 (1) ◽

Author(s):

Jonathan Kuten ◽

David Sarid ◽

Ofer Yossepowitch ◽

Nicola J. Mabjeesh ◽

Einat Even-Sapir

Keyword(s):

Prostate Cancer ◽

Metastatic Prostate Cancer ◽

Added Value ◽

Response To Treatment ◽

Pet Ct ◽

Monitoring Response

Download Full-text

181 Bicalutamide (‘Casodex’) 150 mg as adjuvant to radical prostatectomy significantly increases progression-free survival in patients with early non-metastatic prostate cancer: Analysis at a median follow-up of 5.4 years

European Urology Supplements ◽

10.1016/s1569-9056(04)90182-0 ◽

2004 ◽

Vol 3 (2) ◽

pp. 48 ◽

Author(s):

M. Wirth ◽

P. Iversen ◽

D. McLeod ◽

W. See ◽

C. Morris ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Metastatic Prostate Cancer ◽

Progression Free Survival ◽

Download Full-text